Today 2026.08.05 D-43
Today 
|
Plenary Session 1 CAR T Cell Therapy Sep. 17 (Thu), 10:30-11:50 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Nack-Gyun Chung (College of Medicine, The Catholic University of Korea, Korea) | |
Current Real World Practice to Optimize Outcomes of CAR T Cell Therapy for Pediatric ALL
Children's Hospital of Philadelphia, USA
Eliminating GVHD Prophylaxis: A New Era of Sequential CAR-T and Allogeneic HSCT
The First Affiliated Hospital, Zhejiang University School of Medicine, China
|
Luncheon Symposium 1 Sep. 17 (Thu), 12:00-12:40 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Hee-Je Kim (College of Medicine, The Catholic University of Korea, Korea) | |
Optimizing cGVHD Management After Ruxolitinib Failure: The Role of Belumosudil in Clinical Practice
The First Affiliated Hospital of Soochow University, China
|
Luncheon Symposium 2 Sep. 17 (Thu), 12:00-12:40 |
Room C (2F) |
|
|---|---|---|
| Chair(s) | Seok Jin Kim (Sungkyunkwan University School of Medicine, Korea) | |
Maintaining Relative Dose Intensity in Elderly DLBCL: Clinical Strategies with Pegfilgrastim
Seoul National University Hospital, Korea
|
Luncheon Symposium 3 Sep. 17 (Thu), 12:00-12:40 |
Room D (2F) |
|
|---|---|---|
| Chair(s) | Deog-Yeon Jo (Chungnam National University College of Medicine, Korea) | |
Optimizing PNH Management with Iptacopan: Insights from Real-World Practice
College of Medicine, The Catholic University of Korea, Korea
|
Plenary Session 2 GVHD Sep. 17 (Thu), 13:00-14:20 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Hee-Je Kim (College of Medicine, The Catholic University of Korea, Korea) | |
Beyond Immunosuppression: Enhancing Tissue Resilience to Mitigate GVHD
Dan L. Duncan Comprehensive Cancer Center, USA
Immunologic Mechanisms and Modulation of Chronic Graft-Versus-Host Disease
University of Minnesota, USA
|
Joint Symposium 1 (ASTCT-KSBMT) Evolving T-cell Manipulation Strategies: Optimization of PTCy and New Frontiers in T Cell Depletion Sep. 17 (Thu), 14:30-16:00 |
Room A (1F) |
|
|---|---|---|
| Chair(s) |
Hyeon-Seok Eom (National Cancer Center, Korea) Margaret MacMillan (University of Minnesota, USA) |
|
Advances in Ex Vivo T Cell Depletion
University of Minnesota, USA
Selective T cell Depletion and Enrichment
Fred Hutchinson Cancer Center, USA
Optimizing T-Cell Modulation in Adult ALL Transplantation: ATG, PTCy, and Donor-Specific GVHD Control
College of Medicine, The Catholic University of Korea, Korea
|
Scientific Session 1 Next-Generation Immune Effector Cell Therapies: Emerging Platforms and Biological Insights Sep. 17 (Thu), 14:30-16:00 |
Room B (1F) |
|
|---|---|---|
| Chair(s) |
Seok Jin Kim (Sungkyunkwan University School of Medicine, Korea) Deok Hwan Yang (Chonnam National University Medical School, Korea) |
|
Biomarkers and Immune Fitness Shaping Outcomes of Immune Effector Cell Therapies
Dana-Farber Cancer Institute, USA
In Vivo CAR-T Engineering for Lymphoid Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China
Overcoming Resistance in T-cell Malignancies: From Phase 1 Study of CD5-targeted Allogeneic CAR-NK Cells
University of Ulsan College of Medicine, Korea
|
Scientific Session 2 Advances in Immunotherapy and Transplant Strategies in Pediatric Hematologic Malignancies Sep. 17 (Thu), 14:30-16:00 |
Room C (2F) |
|
|---|---|---|
| Chair(s) |
Keon Hee Yoo (Sungkyunkwan University School of Medicine, Korea) Jun Eun Park (Korea University College of Medicine, Korea) |
|
Virus-specific T Cells for Adoptive Immunotherapy
Dana-Farber Cancer Institute, USA
Strategies for Determining Treatment Flow of CAR T-Cell Therapy and HSCT in Pediatric ALL
Wroclaw Medical University, Poland
Clinical Applications of Donor Lymphocyte Infusion in Pediatric Malignancies
Sungkyunkwan University School of Medicine, Korea
|
Education Session 1 Additional Cellular Support after Allogeneic Transplantation Sep. 17 (Thu), 14:30-16:00 |
Room D (2F) |
|
|---|---|---|
| Chair(s) |
Yeung-Chul Mun (Ewha Womans University College of Medicine, Korea) Hyoung Soo Choi (Seoul National University College of Medicine, Korea) |
|
Management of Poor Graft Function in Chilren
Korea University College of Medicine, Korea
Donor Lymphocyte Infusion (DLI) in 2026: Indications, Dosing, and GVHD Trade-offs
University of Ulsan College of Medicine, Korea
Cellular Support Beyond the Graft: Integrative Strategis after Allogeneic HSCT
Case Western Reserve University School of Medicine, USA
|
Joint Symposium 2 (EBMT-KSBMT) Evolving Donor Issues in Allogeneic HSCT: From HLA Matching to Germline Screening and Emerging Concerns Sep. 17 (Thu), 16:50-18:30 |
Room A (1F) |
|
|---|---|---|
| Chair(s) |
Nack-Gyun Chung (College of Medicine, The Catholic University of Korea, Korea) Ibrahim Yakoub-Agha (Lille University Hospital, France) |
|
Germline Traits and Donor Selection for Allo-HCT: on Overview and the Paradigm of DDX41
University of Tor Vergata, Italy
Which Donor Should We Use in the Absence of a Matched Sibling in Aplastic Anemia?
La Fe University and Polytechnic Hospital, Spain
Clonal Hematopoiesis in Hematopoietic Stem Cell Transplantation
Seoul National University College of Medicine, Korea
Hematopoietic Stem Cell Donor Selection in 2026: Evolving Perspectives and Current Challenges
University of Ulsan College of Medicine, Korea
|
Scientific Session 3 Post-Transplant Residual Disease in Acute Leukemia: Monitoring and Therapeutic Strategies Sep. 17 (Thu), 16:50-18:20 |
Room B (1F) |
|
|---|---|---|
| Chair(s) |
Myungshin Kim (The Catholic University of Korea, Korea) Ho-Jin Shin (Pusan National University School of Medicine, Korea) |
|
Flow Cytometric MRD for AML: Updates in 2026
Amsterdam UMC, The Netherlands
Targeting Residual Disease after Transplant: The Convergence of HCT and Engineered Cellular Therapies
Columbia University Irving Medical Center, USA
Clinical Experience with NGS-based Chimerism Analyses in HSCT Patients
Yonsei University College of Medicine, Korea
|
Scientific Session 4 Science Behind Treatment Response and Relapse Sep. 17 (Thu), 16:50-18:20 |
Room C (2F) |
|
|---|---|---|
| Chair(s) |
Won-Sik Lee (Inje University College of Medicine, Korea) Sung-Soo Yoon (Seoul National University College of Medicine, Korea) |
|
Longitudinal Single-Cell Dissection of Venetoclax Resistance in Secondary AML
UNIST, Korea
Improving Post-transplant Immunological Outcome in AML by Modulating VISTA
Vanderbilt University Medical Center, USA
Immune Escape as a Mechanism of Post-transplant Relapse
Taussig Cancer Institute, USA
|
Satellite Symposium 1 Sep. 18 (Fri), 08:30-09:00 |
Room C (2F) |
|
|---|---|---|
| Chair(s) | Sung-Yong Kim (Konkuk University School of Medicine, Korea) | |
Triple Targeting in Myelofibrosis with Momelotinib: An Integrated Therapeutic Approach via JAK1/2 and ACVR1 Inhibition
Soonchunhyang University Seoul Hospital, Korea
|
Satellite Symposium 2 Sep. 18 (Fri), 08:30-09:00 |
Room D (2F) |
|
|---|---|---|
| Chair(s) | Ki-Seong Eom (College of Medicine, The Catholic University of Korea, Korea) | |
Immune Reconstitution and Infection Prevention After CAR T-cell and Bispecific Antibody Therapies: The Evolving Role of IVIG
Seoul National University College of Medicine, Korea
|
Joint Symposium 3 (East Asia Collaborative Session) The CAR-T Landscape in East Asia: Approvals, Coverage, Domestic Development, and Regulatory Frameworks for Cell and Gene Therapy Sep. 18 (Fri), 10:10-11:50 |
Room A (1F) |
|
|---|---|---|
| Chair(s) |
Hyeon-Seok Eom (National Cancer Center, Korea) Su-Peng Yeh (China Medical University Hospital, Taiwan) |
|
Insights into the Development of Cellular Therapy in China: Current Landscape and Future Directions
National Clinical Research Center for Hematologic Disease, China
Chimeric Antigen Receptor T-cell Therapy for Lymphoma in Korea: Current Status, Challenges, and Future Directions
University of Ulsan College of Medicine, Korea
Unlocking Access of CAR-T therapy in Taiwan: From Dual-Track Regulatory Transformation to National Insurance Breakthroughs
National Taiwan University Cancer Center, Taiwan
Current Status and Challenges of CAR-T Cell Products in Japan: A Regulatory Perspective
Pharmaceuticals and Medical Devices Agency, Japan
|
Scientific Session 5 AML/MDS Biology Sep. 18 (Fri), 10:10-11:40 |
Room B (1F) |
|
|---|---|---|
| Chair(s) |
Jae-Sook Ahn (Chonnam National University Medical School, Korea) Chul Won Jung (Sungkyunkwan University School of Medicine, Korea) |
|
Leukemic Stem Cells in AML: Mechanisms, Detection, and Therapeutic Targeting
New York University Grossman School of Medicine, USA
Single-cell Genomics for Predicting and Dissecting Venetoclax Resistance in Monocytic AML
Moffitt Cancer Center & Research Institute, USA
Information-driven Studeis on AML
College of Pharmacy, Seoul National University, Korea
|
Scientific Session 6 Potential Role of AI in Hematology and Cellular Therapy Sep. 18 (Fri), 10:10-11:40 |
Room C (2F) |
|
|---|---|---|
| Chair(s) |
Yoo Jin Kim (College of Medicine, The Catholic University of Korea, Korea) Jae-Yong Kwak (Jeonbuk National University Medical School, Korea) |
|
AI-Driven Prediction of Transplant Outcomes
University Hospital Essen, Germany
AI-Based Prediction of Early Relapse after CAR-T Therapy
University of California, San Francisco, USA
Clinical Relevance of BM fibrosis in MDS Using Digital Imaging Approaches
Seoul National University College of Medicine, Korea
|
Education Session 2 Toxicities of Transplant and Immunotherapy Sep. 18 (Fri), 10:10-11:40 |
Room D (2F) |
|
|---|---|---|
| Chair(s) |
Hyoung Jin Kang (Seoul National University College of Medicine, Korea) Hyeon Jin Park (National Cancer Center, Korea) |
|
Autoimmune Cytopenia and Pure Red Cell Aplasia after HSCT
Seoul National University College of Medicine, Korea
Best Anti-fungal Prophylaxis and Treatment pre-/post-HSCT
The Catholic University of Korea, Korea
Real World Management of CAR T Cell Toxicities-expert Opinion
Children's Hospital of Philadelphia, USA
|
Luncheon Symposium 4 Sep. 18 (Fri), 12:00-12:40 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Byung Sik Cho (College of Medicine, The Catholic University of Korea, Korea) | |
From Diagnosis to Transplant: Optimizing the Transplant Bridging Strategy in Secondary AML
Seoul National University College of Medicine, Korea
|
Luncheon Symposium 5 Sep. 18 (Fri), 12:00-12:40 |
Room C (2F) |
|
|---|---|---|
| Chair(s) | Kihyun Kim (Sungkyunkwan University School of Medicine, Korea) | |
Unlocking the Clinical Value of Early CAR-T Therapy in Multiple Myeloma: Insights from the CARTITUDE-4 Experience
Seoul National University College of Medicine, Korea
|
Luncheon Symposium 6 Sep. 18 (Fri), 12:00-12:40 |
Room D (2F) |
|
|---|---|---|
| Chair(s) | Nack-Gyun Chung (College of Medicine, The Catholic University of Korea, Korea) | |
Donor Lymphocyte Infusion after Pediatric Haploidentical HSCT: Indications and Therapeutic Approach
Sungkyunkwan University School of Medicine, Korea
|
Joint Symposium 4 (ISCT-KSBMT) Next-Generation Immune Cell Therapies Beyond CAR-T Sep. 18 (Fri), 13:00-14:30 |
Room A (1F) |
|
|---|---|---|
| Chair(s) |
Je-Jung Lee (Chonnam National University Medical School, Korea) William Hwang (National Cancer Centre Singapore and Singapore General Hospital, Singapore) |
|
Delegated Manufacturing: Bridging the Gap Between Commercial and Point-of-Care Models for Sustainable Advanced Cellular Therapy Programmes
National Cancer Centre Singapore and Singapore General Hospital, Singapore
Fine-tuning Signal Strength in CD5 CAR-NK Cells for Targeted T Cell Cancer Therapy
College of Pharmacy, Yonsei University, Korea
Multispecific T Cell Engagers, γδ T Cells, and NK Cell–Based Immunotherapy
University of Ulsan College of Medicine, Korea
|
Scientific Session 7 Expanding CAR T-Cell Therapy beyond Lymphoid Malignancies: Myeloid Neoplasms, Solid Tumors, and Autoimmune Diseases Sep. 18 (Fri), 13:00-14:30 |
Room B (1F) |
|
|---|---|---|
| Chair(s) |
June-Won Cheong (Yonsei University College of Medicine, Korea) Sung-Hyun Kim (Dong-A University College of Medicine, Korea) |
|
Clinical Translation of Next-Generation Cellular Therapies for Acute Myeloid Leukemia: From Clinical Proof-of-Concept to Hematopoietic Stem Cell–Sparing Immunotherapy
Memorial Sloan Kettering Cancer Center, USA
Next-generation Switchable CAR-T Platform: Enhancing Precision and Efficacy in Solid Tumors
Seoul National University College of Medicine, Korea
Deep B Cell Depletion beyond Hematology: Immune Reset as a New Treatment Paradigm for Autoimmune Diseases
Erlangen-Nürnberg, Germany
|
Nursing Session 1 KOR Multidisciplinary Approach to Hematopoietic Stem Cell Transplantation Patients I Sep. 18 (Fri), 13:00-14:30 |
Room C (2F) |
|
|---|---|---|
| Chair(s) | EunJung Joo (National Cancer Center, Korea) | |
Ocular Diseases in Hematopoietic Stem Cell Transplantation Patients: Key Indicators for Immediate Recognition
National Cancer Center, Korea
From Diagnostics to Intervention: Managing Infections in Hematology Patients based on Imaging and Lab Results
College of Medicine, The Catholic University of Korea, Korea
|
Education Session 3 Practical Issues in Stem Cell Transplantation 2026 Sep. 18 (Fri), 13:00-14:30 |
Room D (2F) |
|
|---|---|---|
| Chair(s) |
Kyoung Ha Kim (Soonchunhyang University College of Medicine, Korea) Yong Park (Korea University College of Medicine, Korea) |
|
Recent Trends in Conditioning Regimens for Myeloid Malignancies
Chungnam National University College of Medicine, Korea
PTCy as a Universal Platform for GVHD Prophylaxis: Integrating New Standards and Defining the Remaining Role of ATG
Gregorio Marañón University General Hospital, Spain
Adult Cord Blood Transplantation Program for New Centers: A Practical Institutional Guide
Seoul National University College of Medicine, Korea
|
Presidential Symposium Lymphoma Cell Therapy Sep. 18 (Fri), 14:40-15:20 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Hyeon-Seok Eom (National Cancer Center, Korea) | |
Evolution of Cellular Therapies in Management of Lymphoma Patients
University of Pennsylvania, USA
|
Plenary Session 3 HSCT for Non-Malignant Disease Sep. 18 (Fri), 15:20-16:00 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Ho Joon Im (University of Ulsan College of Medicine, Korea) | |
Management of Mixed Chimerism and Graft Failure in Non-malignant Diseases
Dana-Farber Cancer Institute, USA
|
Debate Session 1 KOR Allogeneic HSCT in Patients with AML or MDS with TP53 Alternation Sep. 18 (Fri), 15:20-16:00 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Joon Ho Moon (Kyungpook National University School of Medicine, Korea) | |
To Transplant
Chonnam National University Medical School, Korea
Not to Transplant
Yonsei University College of Medicine, Korea
|
Debate Session 2 KOR HSCT for HLH: Decreased Conditioning Intensity vs. Increased Conditioning Intensity Sep. 18 (Fri), 17:30-18:20 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Kyung-Nam Koh (University of Ulsan College of Medicine, Korea) | |
Reduced Intensity Conditioning
Seoul National University College of Medicine, Korea
Myeloablative Conditioning
Chonnam National University Medical School, Korea
|
Joint Symposium 5 (JSTCT-KSBMT) EBV-Associated Diseases and HSCT: From CAEBV to Post-Transplant Complications Sep. 18 (Fri), 16:50-18:30 |
Room C (2F) |
|
|---|---|---|
| Chair(s) |
Nack-Gyun Chung (College of Medicine, The Catholic University of Korea, Korea) Takahiro Fukuda (National Cancer Center Hospital, Japan) |
|
EBV-Positive T/NK-Cell and B-Cell Lymphoproliferative Diseases: HSCT as Cure and as Complication
Sungkyunkwan University School of Medicine, Korea
Clinicopathological Spectrum of EBV-Positive T/NK-Cell Lymphoproliferative Diseases
Seoul National University College of Medicine, Korea
Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, and Outcomes from Japanese Nationwide Data
Kameda Medical Center, Japan
A Japanese Registry-Based Analysis of Allogeneic Hematopoietic Stem Cell Transplantation for Adult Hemophagocytic Lymphohistiocytosis
Keio University, Japan
|
Scientific Session 8 Advances in HSCT Conditioning Sep. 18 (Fri), 16:50-18:20 |
Room D (2F) |
|
|---|---|---|
| Chair(s) |
Seong Kyu Park (Soonchunhyang University College of Medicine, Korea) Sang Kyun Sohn (Kyungpook National University School of Medicine, Korea) |
|
Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation in 2026
Fred Hutchinson Cancer Center, USA
Allogeneic Hematopoietic Cell Donor Selection in 2026
Memorial Sloan Kettering Cancer Center, USA
Optimal Conditioning in Autologous HSCT
Seoul National University College of Medicine, Korea
|
Satellite Symposium 3 Sep. 19 (Sat), 08:30-09:00 |
Room C (2F) |
|
|---|---|---|
| Chair(s) | Seok Lee (Ewha Womans University College of Medicine, Korea) | |
Ph-positive ALL in 2026: From Precision Immuno-targeted Therapy to Transplantation
College of Medicine, The Catholic University of Korea, Korea
|
Joint Symposium 6 (TSBMT-KSBMT) Endothelial Dysfunction Syndromes after Allogeneic HSCT: From SOS/VOD and TA-TMA to CLS/ES and PRES Sep. 19 (Sat), 09:00-10:00 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Kyung-Nam Koh (University of Ulsan College of Medicine, Korea) | |
Hepatic, Pulmonary, and Systemic Endothelial Injury after Allogeneic HSCT: SOS/VOD, Capillary Leak/Engraftment Syndrome, and IPS/DAH
Hacettepe University, Türkiye
Microvascular and CNS Endothelial Dysfunction (TA-TMA, PRES, GVHD-Related Endothelial Injury)
Korea University College of Medicine, Korea
|
Scientific Session 9 Insights on GVHD Prediction, Prevention and Management Sep. 19 (Sat), 10:10-11:40 |
Room A (1F) |
|
|---|---|---|
| Chair(s) |
Hoon Kook (Chonnam National University Medical School, Korea) Byung Sik Cho (College of Medicine, The Catholic University of Korea, Korea) |
|
Pediatric Chronic GVHD: From Biological Insights to Clinical Management
BC Children's Hospital Research Insitutue, Canada
Immunobiology of GVHD Prevention
Hokkaido University, Japan
Microbiome and GvHD Following Allogeneic HSCT
University of Ulsan College of Medicine, Korea
|
Scientific Session 10 Immune Effector Cell Therapy in Lymphoid Malignancies: From Pivotal Trials to Real-World Practice Sep. 19 (Sat), 10:10-11:40 |
Room C (2F) |
|
|---|---|---|
| Chair(s) |
Jin Seok Kim (Yonsei University College of Medicine, Korea) Young Rok Do (Keimyung University School of Medicine, Korea) |
|
Integrating MRD into CAR T-cell Therapy for ALL: from Patient Selection to Post-treatment Intervention
Memorial Sloan Kettering Cancer Center, USA
Sequencing Cellular Therapy in Multiple Myeloma: Lessons from Trials and Real-world Practice
Medical College of Wisconsin, USA
Real-world CAR‑T Experience in LBCL
The Catholic University of Korea, Korea
|
Nursing Session 2 KOR Sep. 19 (Sat), 10:10-11:10 |
Room D (2F) |
|
|---|---|---|
| Chair(s) | Heejun Kim (Samsung Medical Center, Korea) | |
Radiotherapy in Hematologic Malignancies and Stem Cell Transplantation
National Cancer Center, Korea
Restoring Normal life for Hematology Patients
College of Medicine, The Catholic University of Korea, Korea
